Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 7, 2022; 28(29): 3981-3993
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3981
Published online Aug 7, 2022. doi: 10.3748/wjg.v28.i29.3981
Figure 2 Kaplan–Meier curves of overall and disease-free survival comparing the results of the different treatment modalities (P = 0.
312 and P = 0.0001, respectively). Median overall survival (OS) and disease-free survival (DFS) for the resection group were 53 [95% confidence interval (CI): 31-53] and 19 mo (95%CI: 3-Not Evaluable), respectively. Median OS and DFS for the Trans-Arterial ChemoEmbolization group were 18 (95%CI: 8-31) and 0 (95%CI: 0-2) months, respectively. A: OS; B: DFS. OS: Overall survival; DFS: Disease-free survival; TACE: Trans-Arterial ChemoEmbolization.
- Citation: Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993
- URL: https://www.wjgnet.com/1007-9327/full/v28/i29/3981.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i29.3981